European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

by Marie Weil
February 12, 2021
A A
Share on LinkedinShare on Twitter
  • Sandoz to acquire three established brands sold in more than 100 markets
  • Acquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl
  • Transaction complements Sandoz leadership in generic penicillins with a leading position in cephalosporins – largest antibiotic segment by global sales

Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics.

The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®)) in more than 100 markets. It excludes the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK.

Sandoz will pay GSK USD 350 million at closing, plus additional milestone payments of up to USD 150 million, subject to the terms of the transaction. Closing of the transaction is expected in the second half of 2021, subject to customary closing conditions including regulatory approvals. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

In line with its integrated manufacturing strategy, Sandoz intends in the longer term to manufacture Zinnat® at sites in its own network, which has global antibiotics production centered on its lead production site in Kundl, Austria. Once the transaction is completed, GSK will supply Zinnat® to Sandoz under a manufacturing and supply agreement (MSA), while supporting a transfer of the related manufacturing operations to Sandoz. We expect this process to last for approximately four years from the close of the transaction onwards.

“This important transaction will further position Sandoz as a global leader in antibiotics – truly essential medicines that are the backbone of modern healthcare systems,” said Sandoz CEO Richard Saynor.

“Cephalosporins are the largest antibiotic segment by global sales and acquiring this leading business, including the established global Zinnat® brand, will complement our #1 position in generic penicillins, the other key segment. It will also set us up for additional synergies driven by an increased promotional footprint that will support growth of both the acquired brands and the current existing Sandoz portfolio.”

The agreement confirms the Sandoz commitment to further grow its antibiotics business, following the announcement last year of a joint investment with the Austrian government of more than EUR 150 million to strengthen the long-term competitiveness of its Kundl antibiotic manufacturing site and help to ensure long-term supply resilience.

Kundl is the hub and center of the last major integrated production chain for antibiotics in the western world. Its focus is on generic penicillin products, but the plant also produces finished dosage forms of several generic cephalosporin products.

Tags: < Invest

Related Industries

Health

Siemens Healthineers presents mammography system with groundbreaking new imaging technology

September 28, 2023
Health

Dr. Jost Reinhard appointed new head of Investor Relations at Bayer

September 20, 2023
Health

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

August 29, 2023
Health

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing / Open Innovation

August 23, 2023
Health

Innovative research for malaria control driven by three collaborating parties: Swiss TPH, BASF and Promega

August 18, 2023
Health

SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities

August 15, 2023

Bringing the power of Dow innovation to Labelexpo Europe 2023

September 6, 2023

...

A new Internet Levy threatens Europe’s Creative Industries and Digital Decade targets

September 16, 2023

...

Ericsson and M1 partner to deploy the new generation of 5G routers to enable a future- ready mobile transport network

September 1, 2023

...

Huawei and Ocean Research and Conservation Association (ORCA) Show How They Go About Protecting Ireland Marine Life

September 15, 2023

...

The BMW Group Selects AWS to Power Next-Generation Automated Driving Platform

September 6, 2023

...

The Carlsberg Group welcomes Jacob Aarup-Andersen as new Chief Executive Officer

September 1, 2023

...

LG Magna e-Powertrain Expands Footprint With New Facility in Hungary

September 5, 2023

...

Hyundai-Kia’s Head of Battery and H2 Fuel Cell Development Chang Hwan Kim Elected as President of FISITA from ’25-’27

September 14, 2023

...

Menzies Aviation renews Jazeera Airways contract in Kuwait and wins new business in Europe and Pakistan

September 6, 2023

...

Huawei Ireland launches new 2023 STEM programme with global prize fund of $100K

September 13, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist